Similarly, 24 pairs were obtained from patients with early HER2-positive breast cancer treated in a neoadjuvant regimen (Figure S12), revealing a significant increase in YAP1/TAZ expression: 75% of post-treatment samples with residual tumor showed increased YAP1/TAZ expression as compared to their pre-treatment samples (p = 0.001), whereas the remainder did not vary (Figure 7D). This evidence concerns the gene ERBB2 and breast cancer.